Yuan Junying
Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
Apoptosis. 2009 Apr;14(4):469-77. doi: 10.1007/s10495-008-0304-8.
It has been a major challenge to develop effective therapeutics for stroke, a leading cause of death and serious debilitation. Intensive research in the past 15 years have implicated many regulators and the related mechanisms by which neuronal cell death is regulated. It is now clear that even a brief ischemic stroke may trigger complex cellular events that lead to both apoptotic and necrotic neuronal cell death in a progressive manner. Although efforts at developing specific chemical inhibitors for validated targets have been successful for in vitro enzymatic assays, the development of some of such inhibitors into human therapy has been often hindered by their in vivo bioavailability profile. Considerations for the ability to chemically target a cellular mechanism in manner compatible with disease targets in vivo might be emphasized early in the development process by putting a priority on identifying key targets that can be effectively targeted chemically. Thorough interrogation of cellular pathways by saturation chemical genetics may provide a novel strategy to identify multiple key molecular entities that can be targeted chemically in order to select a target suitable for the treatment of intended human diseases such as stroke.
中风是导致死亡和严重残疾的主要原因,开发有效的中风治疗方法一直是一项重大挑战。在过去15年里的深入研究已经揭示了许多调节因子以及调节神经元细胞死亡的相关机制。现在很清楚,即使是短暂的缺血性中风也可能引发复杂的细胞事件,这些事件会以渐进的方式导致凋亡性和坏死性神经元细胞死亡。尽管为经过验证的靶点开发特异性化学抑制剂在体外酶分析中取得了成功,但其中一些抑制剂在转化为人体治疗时常常因其体内生物利用度而受阻。在开发过程早期,可能需要强调以与体内疾病靶点相兼容的方式对细胞机制进行化学靶向的能力,优先确定能够被有效化学靶向的关键靶点。通过饱和化学遗传学对细胞通路进行全面探究,可能提供一种新策略,以识别多个能够被化学靶向的关键分子实体,从而选择一个适合治疗中风等人类疾病的靶点。